ID: ALA5289212

Max Phase: Preclinical

Molecular Formula: C23H29N3O4

Molecular Weight: 411.50

Representations

Canonical SMILES:  C[C@H]1[C@H](n2nncc2-c2ccccc2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3

Standard InChI:  InChI=1S/C23H29N3O4/c1-14-9-10-18-15(2)20(26-19(13-24-25-26)16-7-5-4-6-8-16)27-21-23(18)17(14)11-12-22(3,28-21)29-30-23/h4-8,13-15,17-18,20-21H,9-12H2,1-3H3/t14-,15-,17+,18+,20-,21-,22-,23-/m1/s1

Standard InChI Key:  ZEXDARZDSWLDEZ-DFIIIMEYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 411.50

Molecular Weight (Monoisotopic): 411.2158

AlogP: 4.33

#Rotatable Bonds: 2

Polar Surface Area: 67.63

Molecular Species: NEUTRAL

HBA: 7

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 0.44

CX LogP: 4.94

CX LogD: 4.94

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.69

Np Likeness Score: 1.67

References

1. Gao F, Sun Z, Kong F, Xiao J..  (2020)  Artemisinin-derived hybrids and their anticancer activity.,  188  [PMID:31945642] [10.1016/j.ejmech.2020.112044]

Source

Source(1):

• Scientific Literature